LambdaVision Raises $7 Million to Advance Space‑Manufactured Artificial Retina Technology
LambdaVision, a Connecticut biotech company pioneering a novel protein‑based artificial retina to restore sight in patients with retinal degenerative diseases, has secured substantial financial backing across multiple funding rounds that position it to accelerate preclinical development and scale innovative manufacturing. The company’s approach leverages the unique microgravity environment aboard the International Space Station to produce highly uniform protein thin films that form the basis of its investigational artificial retina technology, which targets conditions such as retinitis pigmentosa and age‑related macular degeneration.
In November 2025, LambdaVision announced the closing of a $7 million seed funding round co‑led by Seven Seven Six and Aurelia Foundry Fund, with additional participation from Seraphim Space. This latest financing provides the company with financial runway into 2027 and is earmarked to support the advancement of preclinical development as well as the scale‑up of space‑enabled manufacturing of its artificial retina product. The round reflects growing investor confidence in LambdaVision’s potential to transform treatments for blindness through space‑based biomanufacturing.
Seven Seven Six, an early‑stage venture capital firm founded by technology entrepreneur Alexis Ohanian, has become an influential supporter of LambdaVision’s vision of harnessing microgravity for human health breakthroughs. Aurelia Foundry Fund, a deep tech VC spun out of MIT with a focus on space‑derived technologies, also reinforced its commitment through participation in this co‑leading role. Seraphim Space, known for investing in space tech and ventures leveraging orbital environments, further expanded the investor base backing LambdaVision’s work.
Earlier in May 2024, the company announced the first closing of its initial seed round, led by Aurelia Foundry Fund with participation from Boryung Pharmaceutical and E2MC Ventures. While specific financial figures for that closing were not disclosed publicly, that seed financing was intended to support Good Manufacturing Practice (GMP) scale‑up efforts and critical efficacy and toxicity studies to advance the artificial retina toward clinical trials. This foundational funding played a key role in validating investor interest and in enabling LambdaVision to expand its scientific and manufacturing capabilities.
Beyond venture and seed funding, LambdaVision’s development efforts have benefited from significant non‑dilutive support, particularly through government and research agency awards. For example, the company has been awarded NASA Small Business Innovation Research (SBIR) and NASA Phase 2 In Space Production Applications (InSPA) awards, which support further development of layer‑by‑layer manufacturing processes in low‑Earth orbit. These awards aim to enhance production quality and scalability — critical components for future commercialization and clinical translation of the artificial retina.
LambdaVision’s cumulative funding footprint has been notable: the company has secured more than $18 million in total support, including contributions from NASA and other federal research agencies such as the National Science Foundation and the National Institutes of Health. This diversified financial backing underscores both scientific progress and external confidence in the company’s space‑based manufacturing paradigm.
Historically, LambdaVision’s investors have included a mix of venture capital firms, corporate partners, and research institutions, reflecting the interdisciplinary nature of its mission. In the company’s earlier days, investment and support were provided through mechanisms such as the Connecticut Innovations Bioscience Innovation Fund, which contributed to early product development and commercialization planning.
LambdaVision’s funding strategy — blending venture capital, strategic corporate investment, and government research awards — has enabled the company to sustain a robust development pipeline while advancing both technological innovations and regulatory readiness. These capital injections have supported a series of nine successful microgravity manufacturing missions aboard the International Space Station in partnership with NASA and Space Tango, progressively refining the company’s manufacturing methodology.
With its strengthened financial position and growing roster of investors, LambdaVision is advancing toward its next major milestones, including scaling its space‑enabled manufacturing platform, completing IND‑enabling studies on Earth, and preparing for clinical trials. As the company moves forward, its funding success highlights the increasing intersection of space technology, biotechnology, and venture capital in addressing some of the most challenging unmet needs in human health.
